ArticleJournal of veterinary internal medicine2026
Risk factors associated with elevated serum canine pancreatic lipase immunoreactivity concentration in dogs with hypercortisolism.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypercortisolism (HC) is a common endocrine disorder in dogs that is often associated with pancreatitis. However, the relationship between cortisol concentration, pancreatic injury (PI) markers, and serum specific canine pancreatic lipase immunoreactivity (Spec cPL) concentration elevation remains unclear. HYPOTHESIS/
objectivesTo investigate the prevalence of PI, identify risk factors for elevated Spec cPL, and evaluate changes in Spec cPL concentrations after treatment. ANIMALS: Seventy-one client-owned dogs diagnosed with naturally occurring HC between 2015 and 2024.
methodsRetrospective cross-sectional study with a nested cohort analysis. Dogs were classified as PI (Spec cPL ≥400 μg/L) or non-PI (Spec cPL <400 μg/L). Clinical and laboratory variables, including abdominal ultrasonography findings, were analyzed. Risk factors were identified using logistic regression analysis. A subset of dogs with follow-up data was analyzed to assess changes in Spec cPL concentration after treatment for HC.
resultsThe PI comprised 16 dogs, with 7 (44%) showing ultrasonographic signs of pancreatitis. Univariate analysis showed significant intergroup differences in gamma-glutamyl transferase, blood urea nitrogen (BUN), symmetric dimethylarginine, cholesterol, C-reactive protein, urine protein-to-creatinine ratio (UPC), and post-low-dose dexamethasone suppression test (LDDST) cortisol concentrations. Multivariate analysis further identified BUN (odds ratio [OR], 1.05; 95% CI, 1.01-1.09; P =.02), UPC (OR, 1.84; 95% CI, 1.09-3.11; P =.02), and post-LDDST cortisol (OR, 1.55; 95% CI, 1.11-2.17; P =.01) as risk factors. Trilostane treatment significantly reduced the post-ACTH cortisol and Spec cPL concentrations. CONCLUSIONS AND CLINICAL IMPORTANCE: PI could occur in dogs with HC, especially those having elevated post-LDDST cortisol, BUN, and UPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.